Literature DB >> 15361884

p19ARF directly and differentially controls the functions of c-Myc independently of p53.

Ying Qi1, Mark A Gregory, Zhaoliang Li, Jeffrey P Brousal, Kimberly West, Stephen R Hann.   

Abstract

Increased expression of the oncogenic transcription factor c-Myc causes unregulated cell cycle progression. c-Myc can also cause apoptosis, but it is not known whether the activation and/or repression of c-Myc target genes mediates these diverse functions of c-Myc. Because unchecked cell cycle progression leads to hyperproliferation and tumorigenesis, it is essential for tumour suppressors, such as p53 and p19ARF (ARF), to curb cell cycle progression in response to increased c-Myc (refs 2, 3). Increased c-Myc has previously been shown to induce ARF expression, which leads to cell cycle arrest or apoptosis through the activation of p53 (ref. 4). Here we show that ARF can inhibit c-Myc by a unique and direct mechanism that is independent of p53. When c-Myc increases, ARF binds with c-Myc and dramatically blocks c-Myc's ability to activate transcription and induce hyperproliferation and transformation. In contrast, c-Myc's ability to repress transcription is unaffected by ARF and c-Myc-mediated apoptosis is enhanced. These differential effects of ARF on c-Myc function suggest that separate molecular mechanisms mediate c-Myc-induced hyperproliferation and apoptosis. This direct feedback mechanism represents a p53-independent checkpoint to prevent c-Myc-mediated tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361884     DOI: 10.1038/nature02958

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  96 in total

1.  Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription.

Authors:  Z Li; S R Hann
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

2.  INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury.

Authors:  David H Lee; Jesse M Wolstein; Basu Pudasaini; Matthew Plotkin
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

3.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

Review 4.  MYC and metabolism on the path to cancer.

Authors:  Annie L Hsieh; Zandra E Walton; Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Semin Cell Dev Biol       Date:  2015-08-12       Impact factor: 7.727

5.  Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis.

Authors:  Lior Golomb; Debora Rosa Bublik; Sylvia Wilder; Reinat Nevo; Vladimir Kiss; Kristina Grabusic; Sinisa Volarevic; Moshe Oren
Journal:  Mol Cell       Date:  2012-01-27       Impact factor: 17.970

6.  Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.

Authors:  David N Boone; Ying Qi; Zhaoliang Li; Stephen R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 7.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

8.  Borealin is repressed in response to p53/Rb signaling.

Authors:  Dipali A Date; Cara J Jacob; Mike E Bekier; Andrew C Stiff; Mark W Jackson; William R Taylor
Journal:  Cell Biol Int       Date:  2007-07-15       Impact factor: 3.612

Review 9.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

10.  The tumor suppressor protein HBP1 is a novel c-myc-binding protein that negatively regulates c-myc transcriptional activity.

Authors:  Julienne R Escamilla-Powers; Colin J Daniel; Amy Farrell; Karyn Taylor; Xiaoli Zhang; Sarah Byers; Rosalie Sears
Journal:  J Biol Chem       Date:  2009-12-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.